BioPharmSignal logoBioPharmSignal

Biotech News

Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

Veru Inc (VERU)Veru Inc2026-06-25 13:46 ESTEarnings

VERU (VERU) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is veru.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

VERUVeru Inc2026-06-25 13:46 EST

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

VERUVeru Inc2026-06-25 13:46 EST

Veru Announces Pricing of $25 Million Public Offering

VERUVeru Inc2026-06-25 13:46 EST

Veru to Present Two Abstracts at ObesityWeek 2025

VERUVeru Inc2026-06-25 13:46 EST

Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop

VERUVeru Inc2026-06-25 13:46 EST

Veru to Report Fiscal Year 2025 Financial Results on December 17th

VERUVeru Inc2026-06-25 13:46 EST

Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress

VERUVeru Inc2026-06-25 13:46 EST

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

VERUVeru Inc2026-06-25 13:46 EST

Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

VERUVeru Inc2026-06-25 13:46 EST

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

VERUVeru2026-06-25 13:46 EST

Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th

View all latest news

Veru Inc

VERU is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

VERUVeru Inc2026-06-26 07:27 EST

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

VERUVeru Inc2026-06-26 07:27 EST

Veru Announces Pricing of $25 Million Public Offering

VERUVeru Inc2026-06-26 07:27 EST

Veru to Present Two Abstracts at ObesityWeek 2025

VERUVeru Inc2026-06-26 07:27 EST

Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop

VERUVeru Inc2026-06-26 07:27 EST

Veru to Report Fiscal Year 2025 Financial Results on December 17th

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States